biotech · Lung Cancer · Non-small Cell Lung Cancer (NSCLC) · RVMD
Revolution Medicines
Revolution Medicines is a biotech organization headquartered in Redwood City, USA. It trades on NYSE under ticker RVMD. Primary therapeutic focus areas include Lung Cancer, Non-small Cell Lung Cancer (NSCLC), Non-Small C
700 Saginaw Dr., Redwood City, California 94063, US HQ
2014 Founded
1,050 Employees
Public company Type
RVMD · NYSE Ticker
Company details
- Status
- Public
- HQ
- 700 Saginaw Dr., Redwood City, California 94063, US
- Founded
- 2014
- Employees
- 1,050
- Programs
- 26
- Drugs
- 28
- Patents
- 36
Elironrasib
Phase 2 · small molecule · Non-Small Cell Lung Cancer (NSCLC)
Elironrasib for Non-Small Cell Lung Cancer (NSCLC) is a Phase 2 program (small_molecule) at Revolution Medicines with 1 ClinicalTrials.gov record(s).
Internal code RMC-6291-101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Revolution Medicines
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Non-Small Cell Lung Cancer (NSCLC)
- Status
- active
- Trials
- 1